Check-Cap has a new spin on capsule endoscopy, using X-rays instead of a visual camera. But more compelling clinical data will be necessary if it is to position its…
Illumina’s $1.2bn buy of Pacific Biosciences raises questions about why it shunned another long-read sequencing player, Oxford Nanopore Technologies.
The Swiss group has succeeded with its internally developed diagnostics, but buying in innovation has served Becton Dickinson well.
Guardant Health says its tests have a market opportunity of $35bn, and now has to justify investors’ faith.
Voxeleron is, like Google’s related company Deepmind, using artificial intelligence to analyse ocular images. Unlike Deepmind, it is employing a targeted approach.
Apple has obtained its first FDA clearance, putting the Apple Watch on the same footing as Alivecor’s KardiaBand – but the smaller group is fighting back.
Pfizer is to push Exact’s cancer test in a deal that could “permanently alter the trajectory of Cologuard”.
Deepmind plans more rigorous trials of its ophthalmology AI after early successes.